We are live on ! Find out more
PTCT icon

PTC Therapeutics

118 hedge funds and large institutions have $202M invested in PTC Therapeutics in 2016 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 44 increasing their positions, 33 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

113% more call options, than puts

Call options by funds: $4.23M | Put options by funds: $1.99M

33% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 33

7% more capital invested

Capital invested by funds: $189M → $202M (+$13M)

0% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 22

1% less funds holding

Funds holding: 119118 (-1)

Holders
118
Holders Change
-1
Holders Change %
-0.84%
% of All Funds
3.15%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
22
Increased
44
Reduced
33
Closed
22
Calls
$4.23M
Puts
$1.99M
Net Calls
+$2.24M
Net Calls Change
+$739K
Name Holding Trade Value Shares
Change
Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$1.58M +$12.5K +1,700 +0.8%
PI
27
Putnam Investments
Massachusetts
$1.54M
QI
28
QS Investors
New York
$1.54M +$1.61M +219,206 New
BG
29
BlackRock Group
United Kingdom
$1.42M -$84.2K -11,485 -5%
SDIC
30
South Dakota Investment Council
South Dakota
$1.4M
BIM
31
BlackRock Investment Management
Delaware
$1.29M +$193K +26,361 +17%
SFM
32
Sphera Funds Management
Israel
$1.23M -$554K -75,539 -30%
Deutsche Bank
33
Deutsche Bank
Germany
$1.18M -$1.4M -191,113 -53%
Two Sigma Advisers
34
Two Sigma Advisers
New York
$1.13M -$475K -64,700 -29%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$1.05M +$37K +5,044 +3%
ARTA
36
A.R.T. Advisors
New York
$1.05M -$515K -70,229 -32%
Mackenzie Financial
37
Mackenzie Financial
Ontario, Canada
$970K
TCIM
38
TIAA CREF Investment Management
New York
$923K +$163K +22,167 +20%
NI
39
Numeric Investors
Massachusetts
$887K +$927K +126,400 New
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
$731K +$401K +54,667 +110%
Renaissance Technologies
41
Renaissance Technologies
New York
$715K -$6.21M -846,800 -89%
Dimensional Fund Advisors
42
Dimensional Fund Advisors
Texas
$707K +$739K +100,783 New
Fisher Asset Management
43
Fisher Asset Management
Washington
$670K +$28.9K +3,942 +5%
OC
44
Oppenheimer & Co
New York
$613K +$119K +16,229 +23%
DC
45
Davenport & Co
Virginia
$577K +$19.1K +2,600 +3%
AllianceBernstein
46
AllianceBernstein
Tennessee
$531K +$168K +22,900 +43%
California State Teachers Retirement System (CalSTRS)
47
California State Teachers Retirement System (CalSTRS)
California
$490K -$14.1K -1,919 -3%
Goldman Sachs
48
Goldman Sachs
New York
$485K +$413K +56,265 +441%
Connor, Clark & Lunn Investment Management (CC&L)
49
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$449K +$373K +50,900 +389%
CWG
50
C WorldWide Group
Denmark
$447K

PTCT Hedge Fund Activity: Q2 2016 in Review

118 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q2 2016, worth a combined $202M — up 6.9% from $189M a quarter earlier.

Fund positioning in PTCT was balanced in Q2 2016: 22 funds opened new positions, 22 closed out, 44 added to existing stakes and 33 trimmed.

The largest buyer was Pictet Asset Management (UK), adding an estimated $7.5M. The largest seller was Sectoral Asset Management, cutting an estimated $14.4M.

  • 118 institutional investors held PTC Therapeutics (PTCT) as of Q2 2016, down from 119 in Q1 2016.
  • Funds reported $202M of PTC Therapeutics stock for Q2 2016, up 6.9% quarter-over-quarter.
  • 22 funds opened new PTC Therapeutics positions in Q2 2016 and 22 closed out, a net change of 0 holders.
  • The largest PTC Therapeutics buyer in Q2 2016 was Pictet Asset Management (UK), an estimated $7.5M added.
  • The largest PTC Therapeutics seller in Q2 2016 was Sectoral Asset Management, an estimated $14.4M sold.

Based on aggregated 13F filings for Q2 2016.